Peter Addy & Michael Mithoefer – Psychedelic-Assisted Therapy: Breakthrough Treatments for Complex Mental Health Disorders
What every clinician needs to know about the new class
of therapeutics propelling mental health treatment into the future
For many clients with PTSD, working through the trauma is too excruciating. That’s why so many drop out of therapy.
But we now have new hope!
Leading research shows adding psychedelic medicines to psychotherapy can quickly improve outcomes when treating trauma, anxiety, depression, and other mental distress.
A study on PTSD published in Nature Medicine in May 2021 revealed 67% of participants treated with three MDMA-assisted sessions no longer met the diagnostic criteria for PTSD 18 weeks after baseline.
Researchers found using MDMA with psychotherapy helps trauma survivors engage with traumatic memories while also reducing the defensiveness and fear normally associated with them…
Allowing the client to deal with whatever problems they’re experiencing… Without being overwhelmed, dissociating, or numbing.
The best part? You can integrate psychedelic medicines with modalities you’re already using.
Now you can be part of this exciting new world of therapy with this all-new online training!
Register today to get skills and strategies that help clients find deep and lasting transformation.
Psychedelic-Assisted Therapy: Breakthrough Treatments for Complex Mental Health Disorders
$609.95 * Value
Just $124.95 Today — Stunning Savings!
GET STARTED NOWOngoing clinical trials in the United States, United Kingdom, and Europe will likely result in more psychedelic medicines available for legal use in the U.S.
In fact, we already have access to some of these tools!
In 2020, the FDA granted Breakthrough Therapy Designation (BTD) to a ketamine-based medicine as a treatment for adults with major depressive disorder with acute suicidal ideation or behavior.
It’s the first FDA-approved medicine available shown to reduce depressive symptoms within 24 hours… As opposed to typical antidepressants, which only work for 40%-60% of patients and take weeks or months to work.
As research continues to reveal the healing power of psychedelics, there will be a surge in demand for trained therapists who are ready to conduct psychedelic-assisted psychotherapy.
This online training is an excellent starting point to prepare yourself for this journey. You’ll discover:
- Interventions grounded in neuroscience and next-stage medicinal psychedelics
- The truth about psychedelics throughout history and across cultures
- How these medicines are used in carefully designed clinical trials
- How they work in the body and brain
- How your clients use them in the real world
- And so much more!
Download today to get the lowest price on this groundbreaking course that will move you toward the future of behavioral health treatment!
It’s important to note the psychedelics themselves are NOT a treatment or a “cure” for a disorder. They are used under your professional supervision as a catalyst to facilitate trauma processing during psychotherapy. Also, psychedelic-assisted therapy is NOT for everyone. But it has been shown to be a useful tool when all else has failed to get the client’s desired results.
Psychedelic-Assisted Therapy: Breakthrough Treatments for Complex Mental Health Disorders
$609.95 * Value
Just $124.95 Today — Stunning Savings!
GET STARTED NOWThis Course For
- Addiction Counselors
- Counselors
- Psychologists
- Marriage and Family Therapists
- Physicians
- Nurses
- Psychotherapists
- Psychiatrists
- Social Workers
- Therapists
- Other Mental Health Professionals
WHAT YOU'LL FIND IN THIS COURSE
Psychedelics, Hallucinogens And Entheogens
In this introductory session, Peter H. Addy, PhD, LPC, LMHC, provides a foundation for understanding the history, research, ethics and applications of psychedelics.
Types of Psychedelic Substances
Know the properties and differences between:
- Classic psychedelics
- Empathogens
- Dissociatives
- Complex psychedelics
- Atypical psychedelics
History & Context of Psychedelic Use
In this section, you'll discover:
- A history of psychedelic use
- How these medicines work in the brain
- Safety considerations
- Difference between "street drugs" and medicinal psychedelics
- What the research shows about using medicinal psychedelics for mental health treatment...
Legal Avenues for Experiencing Psychedelics: Paths Clients May Take
Discover current ways people access psychedelics, such as:
- Retreat centers and guided tourism
- Mushroom women in the Mazatec lands, Jan Kounen's Controlled Use
- Ketamine & cannabis clinics
- And much more...
Ethical Considerations for Your Client & In the Therapy Room
Learn how to navigate ethical challenges, including:
- Sexual abuse in psychedelic communities
- Substance use by facilitators in community
- Assessment strategies to determine high risk
- Spiritual bypassing: Using psychedelics to avoid working on yourself
- And more...
Psychotherapy Preparation & Integration
In this section, you'll cover:
- Pre-session counseling
- Grounding techniques
- The therapeutic protocol
- And post-counseling techniques
Psychedelics in Therapy: New Ways to Catalyze Healing
In Session 2, Michael Mithoefer, MD, provides:
- A history of MDMA and safety data from overview of completed clinical trials
- Results of six completed MDMA Phase 2 clinical trials
- Details of ongoing Phase 3 trials of MDMA-assisted psychotherapy
- Status of FDA drug development – MDMA and psilocybin, including breakthrough therapy designation
- Therapist training program for MDMA-assisted psychotherapy
- And a whole lot more!
MDMA-Assisted Psychotherapy & Ecstasy: Cutting-Edge Research, Assessment & Intervention for Trauma, Anxiety & More
In this session, Peter H. Addy, PhD, LPC, LMHC, covers:
MDMA vs. Ecstasy
- How MDMA works in the brain & body
- Assessment strategies for ecstasy use
- Risks associated with ecstasy use
The Science Behind MDMA-Assisted Therapy
- Clinical trials: Completed & ongoing research into PTSD, social anxiety in autistic adults, end-of-life anxiety, and more
- Chronic illness & its use
- Limitations of the research & potential risks
Evidence-Based Clinical Skills for Better Treatment
- Non-directive psychotherapy
- Somatic approaches
- Therapeutic stance: Letting the client lead
- Case studies: Research participants tell their own stories
Legal & Ethical Considerations
- Changing legal frameworks: Phase 3 clinical trials, rescheduling MDMA and FDA Expanded Access program opportunities
- Ethical concerns, including access and equity, informed consent and sexual trauma
When you Download today, you'll receive 2 FREE bonuses ($119.98 value!)
Psychedelics in Modern Healing, Digital Seminar with Gabor Maté, MD
This seminar focuses on the lived experience of both clients and therapists that psychedelics can facilitate. You'll discover how to:
- Assess the differences between various psychedelic substances and their potential uses in a therapeutic setting
- Explore the necessity of preparing for a psychedelic-based session with clients
- Integrate what the client experienced and learned in a psychedelic journey after the session
- And MUCH more!
Psychedelic-Assisted Therapy: The Psychotherapy Whose Time Has Come, Digital Seminar with Janis Phelps, PhD
In this training, Dr. Phelps covers:
- A review of the clinical research outcomes on psychedelic-assisted therapy for depression, anxiety, PTSD, end-of-life distress, and substance abuse
- The neuropharmacology of psychedelics
- Multidisciplinary Association for Psychedelic Studies (MAPS) and the California Institute of Integral Studies (CIIS) professional trainings
- The place for such training for licensed psychotherapists and medical professionals
- The future of the research
- Where psychedelics fit within the newest innovations in the mental health field
- And much more!
Peter H Addy, PhD, LPC, LMHC, has studied psychedelic substances and states and consciousness for 15 years. He earned a PhD in clinical psychology studying transcendence, wholeness, and transformation and conducted one of the earliest studies of the atypical psychedelic plant Salvia divinorum in humans. He continued refining his research and clinical skills at Yale University where he studied Salvia and other atypical psychedelics and co-founded the Yale Psychedelic Science Group. He has completed postdoctoral training in substance use disorder treatment, participated in non-directive harm reduction and integration training at Burning Man, and traveled to Mexico to learn about indigenous use of psychedelic plants among the Mazatec people. He is currently a psychotherapist in private practice in Washington and Oregon.
Dr. Addy has presented internationally on a variety of subjects related to spirituality and transpersonal states, psychedelic science, and research methodology. Participants consistently regarded his talks as informative, accessible, and humorous. He has written numerous scientific articles, book chapters, and popular press articles on typical and atypical psychedelics, substance abuse, and spirituality.
Michael Mithoefer, MD, is clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe.
Reviews
There are no reviews yet.